Medical Affairs Strategic Summit 2021 has ended
avatar for Paul J. Rowe, MD, ATSF

Paul J. Rowe, MD, ATSF

Vice President, Head of Global Medical Immunology
Dr. Rowe has well over a decade of research experience spanning from pre-clinical to late phase innovative medical therapy development programs, primarily in respiratory (and cardiovascular) medicine within the pharma industry. He has been directly responsible for medical strategy and lifecycle management of several Chronic Obstructive Pulmonary Disease (COPD), asthma, thrombosis, and cardiovascular medicines. Dr. Rowe has been successfully involved in achieving New Drug Application (NDA) approvals for first in therapeutic class respiratory products and has also led various clinical development global projects from phase II through phase IV clinical trials. He has authored and co-authored several publications in respiratory medicine (COPD and asthma focused primarily) and is a frequent lecturer and speaker at professional society meetings, and educational forums. Dr. Rowe holds degrees from Harvard University and the University of Rochester School of Medicine, is trained in general surgery with additional otolaryngology training, and holds certifications from the London School of Economics and Villanova University.

Dr. Rowe is an active member of several national and international societies and he recently served as Vice Chair of the Drug, Device, Discovery, and Development Committee of the American Thoracic Society (ATS) and has received the distinction of being named a Fellow of the society. He has a primary interest in promoting international medical research collaboration and innovation across government, academia, and industry.

In his current role, Dr. Rowe is responsible for building and leading a Global Medical team and strategy within the Immunology space for novel compounds in mid and late stage development, in various therapeutic disease state indications.